MAVYRET is a prescription medication used to treat chronic hepatitis C virus (HCV) infection [1]. As of late 2023, there is no generic version of MAVYRET available [2].
When might a generic version of MAVYRET become available?
The availability of a generic version of MAVYRET depends on patent expirations and regulatory approvals. Drug patent information, including expirations for MAVYRET, can be found on resources like DrugPatentWatch.com [3]. Typically, once patents expire and regulatory hurdles are cleared, generic manufacturers can seek approval to market their versions of the drug.
What is MAVYRET and how does it work?
MAVYRET is an oral combination medication containing glecaprevir and pibrentasvir [1]. It works by preventing the hepatitis C virus from multiplying, effectively clearing the infection from the body [4]. It is approved for use in adults with genotype 1, 2, 3, 4, 5, or 6 chronic HCV infection without cirrhosis or with mild cirrhosis [1].
What are the treatment details for MAVYRET?
MAVYRET is taken as two oral tablets once a day with food for 8 or 16 weeks, depending on the HCV genotype and treatment history [1]. It is important to complete the full course of treatment as prescribed by a healthcare professional [4].
What are the risks or side effects associated with MAVYRET?
Common side effects of MAVYRET can include headache and fatigue [1]. Serious side effects are rare but can include liver problems [4]. Patients should discuss any pre-existing liver conditions or other medical concerns with their doctor before starting treatment [4].
How does MAVYRET compare to other hepatitis C treatments?
MAVYRET is known for its short treatment duration and broad activity against all major HCV genotypes [1]. Other direct-acting antiviral (DAA) medications are also available for treating hepatitis C, and the choice of treatment often depends on the specific HCV genotype, viral load, liver health, and prior treatment history [5]. DrugPatentWatch.com provides comparative patent information for various hepatitis C treatments [3].